Single enantiomer of YK-4-279 demonstrates specificity in targeting the oncogene EWS-FLI1

Oncotarget

Volumn 3, Issue 2, 2012, Pages 172-182

  Barber Rotenberg, Julie S ^a   Selvanathan, Saravana P ^a   Kong, Yali ^a   Erkizan, Hayriye V ^a   Snyder, Tara M ^b   Peter Hong, S ^c   Kobs, Christina L ^c   South, Natalie L ^c   Summer, Steven ^c   Monroe, Philip J ^c   Chruszcz, Maksymilian ^d   Dobrev, Veselin ^e   Tosso, Perrer N ^a   Scher, Lauren J ^a   Minor, Wladek ^d   Brown, Milton L ^a   Metallo, Steven J ^e   Üren, Aykut ^a   Toretsky, Jeffrey A ^a  

^a GEORGETOWN UNIVERSITY   (United States)

^b ALBANY MOLECULAR RESEARCH INC   (United States)

^c BATTELLE MEMORIAL INSTITUTE   (United States)

^d UNIVERSITY OF VIRGINIA   (United States)

^e GEORGETOWN UNIVERSITY   (United States)

Author keywords

EWS FLi1; RHA; YK 4 279

Indexed keywords

CASPASE 3; EWS FLI FUSION PROTEIN; EWS-FLI FUSION PROTEIN; INDOLE DERIVATIVE; ONCOPROTEIN; RNA BINDING PROTEIN EWS; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FLI 1; YK 4 279; YK 4-279;

ANIMAL; ARTICLE; CELL PROLIFERATION; DRUG ANTAGONISM; EWING SARCOMA; HUMAN; METABOLISM; RAT; SPRAGUE DAWLEY RAT; STEREOISOMERISM; TRANSCRIPTION INITIATION; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; CASPASE 3; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; INDOLES; ONCOGENE PROTEINS, FUSION; PROTO-ONCOGENE PROTEIN C-FLI-1; RATS; RATS, SPRAGUE-DAWLEY; RNA-BINDING PROTEIN EWS; SARCOMA, EWING; STEREOISOMERISM; TRANSCRIPTION FACTORS; TRANSCRIPTIONAL ACTIVATION; TRANSPLANTATION, HETEROLOGOUS;

EID: 84863810354     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.454     Document Type: Article

References (38)

1. Yu H, Kim PM, Sprecher E, Trifonov V, Gerstein M. The importance of bottlenecks in protein networks: correlation with gene essentiality and expression dynamics. PLoS Comput Biol. 2007; 3:e59.
2. Kim J, Pelletier J. Molecular genetics of chromosome translocations involving EWS and related family members. Physiol Genomics. 1999; 1:127-138.
3. Delattre O, Zucman J, Plougastel B, Desmaze C, Melot T, Peter M, Kovar H, Joubert I, de Jong P, Rouleau G, et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature. 1992; 359:162-165.
4. Darnell JE, Jr. Transcription factors as targets for cancer therapy. Nature reviews Cancer. 2002; 2:740-749.
5. Wright PE, Dyson HJ. Intrinsically unstructured proteins: re-assessing the protein structure-function paradigm. Journal of molecular biology. 1999; 293:321-331.
6. Bhalla J, Storchan GB, MacCarthy CM, Uversky VN, Tcherkasskaya O. Local flexibility in molecular function paradigm. Molecular & cellular proteomics: MCP. 2006; 5:1212-1223.
7. Dunker AK, Brown CJ, Lawson JD, Iakoucheva LM, Obradovic Z. Intrinsic disorder and protein function. Biochemistry. 2002; 41:6573-6582.
8. Follis AV, Hammoudeh DI, Wang H, Prochownik EV, Metallo SJ. Structural rationale for the coupled binding and unfolding of the c-Myc oncoprotein by small molecules. Chemistry & biology. 2008; 15:1149-1155.
9. Hammoudeh DI, Follis AV, Prochownik EV, Metallo SJ. Multiple independent binding sites for small-molecule inhibitors on the oncoprotein c-Myc. Journal of the American Chemical Society. 2009; 131:7390-7401.
10. Ng KP, Potikyan G, Savene RO, Denny CT, Uversky VN, Lee KA. Multiple aromatic side chains within a disordered structure are critical for transcription and transforming activity of EWS family oncoproteins. Proceedings of the National Academy of Sciences of the United States of America. 2007; 104:479-484.
11. Erkizan HV, Uversky VN, Toretsky JA. Oncogenic partnerships: EWS-FLI1 protein interactions initiate key pathways of Ewing's sarcoma. Clinical cancer research: an official journal of the American Association for Cancer Research. 2010; 16:4077-4083.
12. Toretsky JA, Erkizan V, Levenson A, Abaan OD, Parvin JD, Cripe TP, Rice AM, Lee SB, Uren A. Oncoprotein EWS-FLI1 activity is enhanced by RNA helicase A. Cancer research. 2006; 66:5574-5581.
13. Uren A, Tcherkasskaya O, Toretsky JA. Recombinant EWSFLI1 oncoprotein activates transcription. Biochemistry. 2004; 43:13579-13589.
14. Erkizan HV, Kong Y, Merchant M, Schlottmann S, Barber-Rotenberg JS, Yuan L, Abaan OD, Chou TH, Dakshanamurthy S, Brown ML, Uren A, Toretsky JA. A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma. Nature medicine. 2009; 15:750-756.
15. Caldwell J. Importance of stereospecific bioanalytical monitoring in drug development. Journal of chromatography A. 1996; 719:3-13.
16. Fassihi AR. Racemates and enantiomers in drug development. International Journal of Pharmaceutics. 1993; 92:1-14.
17. Eriksson T, Bjorkman S, Hoglund P. Clinical pharmacology of thalidomide. European journal of clinical pharmacology. 2001; 57:365-376.
18. United States Food and Drug Administration: FDA's Policy Statement on the Development of New Stereoisomeric Drugs. 1992.
19. Caner H, Groner E, Levy L, Agranat I. Trends in the development of chiral drugs. Drug discovery today. 2004; 9:105-110.
20. Sanchez G, Bittencourt D, Laud K, Barbier J, Delattre O, Auboeuf D, Dutertre M. Alteration of cyclin D1 transcript elongation by a mutated transcription factor up-regulates the oncogenic D1b splice isoform in cancer. Proceedings of the National Academy of Sciences of the United States of America. 2008; 105:6004-6009.
21. Dunker AK, Lawson JD, Brown CJ, Williams RM, Romero P, Oh JS, Oldfield CJ, Campen AM, Ratliff CM, Hipps KW, Ausio J, Nissen MS, Reeves R, Kang C, Kissinger CR, Bailey RW et al. Intrinsically disordered protein. Journal of molecular graphics & modelling. 2001; 19:26-59.
22. Kolenko VM, Uzzo RG, Bukowski R, Finke JH. Caspasedependent and -independent death pathways in cancer therapy. Apoptosis: an international journal on programmed cell death. 2000; 5:17-20.
23. Susin SA, Lorenzo HK, Zamzami N, Marzo I, Snow BE, Brothers GM, Mangion J, Jacotot E, Costantini P, Loeffler M, Larochette N, Goodlett DR, Aebersold R, Siderovski DP, Penninger JM, Kroemer G. Molecular characterization of mitochondrial apoptosis-inducing factor. Nature. 1999; 397:441-446.
24. Li LY, Luo X, Wang X. Endonuclease G is an apoptotic DNase when released from mitochondria. Nature. 2001; 412:95-99.
25. Hegde R, Srinivasula SM, Zhang Z, Wassell R, Mukattash R, Cilenti L, DuBois G, Lazebnik Y, Zervos AS, Fernandes-Alnemri T, Alnemri ES. Identification of Omi/HtrA2 as a mitochondrial apoptotic serine protease that disrupts inhibitor of apoptosis protein-caspase interaction. The Journal of biological chemistry. 2002; 277:432-438.
26. Demichelis F, Fall K, Perner S, Andren O, Schmidt F, Setlur SR, Hoshida Y, Mosquera JM, Pawitan Y, Lee C, Adami HO, Mucci LA, Kantoff PW, Andersson SO, Chinnaiyan AM, Johansson JE et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene. 2007; 26:4596-4599.
27. Nam RK, Sugar L, Wang Z, Yang W, Kitching R, Klotz LH, Venkateswaran V, Narod SA, Seth A. Expression of TMPRSS2:ERG gene fusion in prostate cancer cells is an important prognostic factor for cancer progression. Cancer biology & therapy. 2007; 6:40-45.
28. Rajput AB, Miller MA, De Luca A, Boyd N, Leung S, Hurtado-Coll A, Fazli L, Jones EC, Palmer JB, Gleave ME, Cox ME, Huntsman DG. Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers. Journal of clinical pathology. 2007; 60:1238-1243.
29. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA, Chinnaiyan AM. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005; 310:644-648.
30. Jeon IS, Davis JN, Braun BS, Sublett JE, Roussel MF, Denny CT, Shapiro DN. A variant Ewing's sarcoma translocation (7;22) fuses the EWS gene to the ETS gene ETV1. Oncogene. 1995; 10:1229-1234.
31. Kaneko Y, Yoshida K, Handa M, Toyoda Y, Nishihira H, Tanaka Y, Sasaki Y, Ishida S, Higashino F, Fujinaga K. Fusion of an ETS-family gene, EIAF, to EWS by t(17;22) (q12;q12) chromosome translocation in an undifferentiated sarcoma of infancy. Genes, chromosomes & cancer. 1996; 15:115-121.
32. Peter M, Couturier J, Pacquement H, Michon J, Thomas G, Magdelenat H, Delattre O. A new member of the ETS family fused to EWS in Ewing tumors. Oncogene. 1997; 14:1159-1164.
33. Rahim S, Beauchamp EM, Kong Y, Brown ML, Toretsky JA, Uren A. YK-4-279 inhibits ERG and ETV1 mediated prostate cancer cell invasion. PloS one. 2011; 6:e19343.
34. Otwinowski Z, Minor W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 1997; 276:307-326.
35. Sheldrick GM. A short history of SHELX. Acta Crystallogr A. 2008; 64:112-122.
36. Minor W, Cymborowski M, Otwinowski Z, Chruszcz M. HKL-3000: the integration of data reduction and structure solution. From diffraction images to an initial model in minutes. Acta Crystallogr. 2006; 62:859-866.
37. Jones TA, Zou JY, Cowan SW, Kjeldgaard M. Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr A. 1991; 47 (Pt 2):110-119.
38. Prieur A, Tirode F, Cohen P, Delattre O. EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Mol Cell Biol. 2004; 24:7275-7283.